On January 3, India began vaccinating a section of its teenagers, with Covaxin. About 7.4 crore children, between the ages of 15 and 18, are eligible to receive the COVID-19 vaccine. As of Saturday, over 2 crore children had received the first dose of their vaccine. Only Covaxin was approved for use in this age group, even though, last October, India's first DNA vaccine, ZyCoV-D, had been granted emergency use authorisation for use in children above the age of 12. Some experts have argued that since COVID-19 in children is, in general, not severe, the entire adult population should have been vaccinated first -- over 90% of the eligible population has received the first dose, but second dose coverage remains less than 70%. However, others have pointed out that now that adult vaccination is well underway and progressing, the programme needed to be opened to children as well.\xa0\nIndia has also announced precautionary doses -- a third dose of the vaccine -- for healthcare and frontline workers as well as adults aged above 60 with co-morbidities. The move comes amidst a global surge in COVID-19 cases, with new variant of concern, Omicron, dominating. Unlike some other countries however, India will give beneficiaries the same dose they had for the first two -- either Covishield or Covaxin, without any mixing of the vaccines.\nSo how did the children's vaccination programme come about, and how is it progressing? Do all adults need a booster dose or will only those at risk require it at present? How does the precautionary dose help protect vulnerable individuals? And will we see more variants in the future?\nGuest: Dr Srinath Reddy, President of the Public Health Foundation of India\xa0\nHost: Zubeda Hamid\xa0\nEdited by Reenu Cyriac